ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SXTP 60 Degrees Pharmaceuticals Inc

0.2298
-0.0082 (-3.45%)
After Hours
Last Updated: 17:29:57
Delayed by 15 minutes

Period:

Draw Mode:

Volume 75,999
Bid Price 0.23
Ask Price 0.2442
News -
Day High 0.2442

Low
0.222

52 Week Range

High
8.65

Day Low 0.227723
Company Name Stock Ticker Symbol Market Type
60 Degrees Pharmaceuticals Inc SXTP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0082 -3.45% 0.2298 17:29:57
Open Price Low Price High Price Close Price Prev Close
0.2382 0.227723 0.2442 0.2298 0.238
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
217 75,999 $ 0.2346095 $ 17,830 - 0.222 - 8.65
Last Trade Time Type Quantity Stock Price Currency
16:11:16 50 $ 0.2215 USD

60 Degrees Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.33M 5.80M - 254k -3.77M -0.65 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

60 Degrees Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SXTP Message Board. Create One! See More Posts on SXTP Message Board See More Message Board Posts

Historical SXTP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.2520.25970.2277230.241392186,607-0.0222-8.81%
1 Month0.2720.300.2277230.259666490,618-0.0422-15.51%
3 Months0.310.3570.2220.2794431221,979-0.0802-25.87%
6 Months0.671.530.2220.8039288460,718-0.4402-65.70%
1 Year3.758.650.2222.16549,891-3.52-93.87%
3 Years3.758.650.2222.16549,891-3.52-93.87%
5 Years3.758.650.2222.16549,891-3.52-93.87%

60 Degrees Pharmaceuticals Description

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.

Your Recent History

Delayed Upgrade Clock